Talimogene laherparepvec (T-VEC) as first-line therapy correlated with best overall response rates (complete response (CR), stable disease (SD), partial response (PR), progressive disease (PD))
| Best overall response rate | |||||
| Total | CR | SD | PR | PD | |
| T-VEC secondline | 43 (48.9%) | 15 (17.0%) | 5 (5.7%) | 8 (9.1%) | 15 (17.0%) |
| T-VEC firstline | 45 (51.1%) | 23 (26.1%) | 3 (3.4%) | 10 (11.4%) | 9 (10.2%) |